Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
32 hedge funds and large institutions have $51.3M invested in Trillium Therapeutics Inc. in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 2 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
86% more capital invested
Capital invested by funds: $27.6M → $51.3M (+$23.7M)
10% more funds holding
Funds holding: 29 → 32 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$2.32M |
| 2 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$1.69M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$1.01M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$967K |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$380K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.12M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$905K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$230K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$131K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$107K |
TRIL Hedge Fund Activity: Q3 2016 in Review
32 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q3 2016, worth a combined $51.3M — up 86% from $27.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TRIL positions and 2 closed out — a net gain of 3 holders — while 13 added to existing stakes and 5 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $2.32M. The largest seller was Millennium Management, cutting an estimated $1.12M.
- 32 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q3 2016, up from 29 in Q2 2016.
- Funds reported $51.3M of Trillium Therapeutics Inc. stock for Q3 2016, up 86% quarter-over-quarter.
- 5 funds opened new Trillium Therapeutics Inc. positions in Q3 2016 and 2 closed out, a net change of +3 holders.
- The largest Trillium Therapeutics Inc. buyer in Q3 2016 was Baker Bros. Advisors, an estimated $2.32M added.
- The largest Trillium Therapeutics Inc. seller in Q3 2016 was Millennium Management, an estimated $1.12M sold.
Based on aggregated 13F filings for Q3 2016.